SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-18-002869
Filing Date
2018-04-17
Accepted
2018-04-17 06:01:12
Documents
6
Period of Report
2018-05-22
Effectiveness Date
2018-04-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2235255zdef14a.htm DEF 14A 382921
2 G247341.JPG g247341.jpg GRAPHIC 19572
3 G969389.JPG g969389.jpg GRAPHIC 7506
4 G881507.JPG g881507.jpg GRAPHIC 8385
5 G30642BGI001.GIF g30642bgi001.gif GRAPHIC 153355
6 G30642BGI002.GIF g30642bgi002.gif GRAPHIC 38663
  Complete submission text file 0001047469-18-002869.txt   697924
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37809 | Film No.: 18757828
SIC: 2834 Pharmaceutical Preparations